Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

Silence Therapeutics plc (NASDAQ:SLN), a biotechnology company specializing in RNA therapeutics, stands at a crucial juncture ...

Akribion Therapeutics ("Akribion"), the early-stage biotech developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announces its exit from stealth and the ...

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that Cohort 3 of its Phase 1 clinical trial ...

Klaus Edvardsen has been named chief medical officer (CMO) of Epitopea, an Anglo-Canadian company developing off-the-shelf RNA-based immunotherapies.

Epitopea, a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies, ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...

Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for applications across infectious disease, immunology, and other therapeutic areas, today ...

No significant safety or dose limiting toxicities reported PK data from Cohorts 1 and 2 consistent with preclinical and Phase 0 trial results BOSTON, Feb. 6 ...

German biotech Akribion Therapeutics has emerged from stealth with 8 million euros ($9 million) in seed funding to accelerate ...

Africa’s EVA Pharma, France’s DNA Script, and Belgium’s Quantoom Biosciences have signed a Memorandum of Understanding which ...